Arvinas, Inc. (ARVN) stock
ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.74−0.02 (-0.37%)
Close on Nov 19, 2026Market cap $440.70MP/E 42.1Yield –
Arvinas net income
Net income is the profit left for shareholders after every expense, interest and tax.
Arvinas's net income for the twelve months ending Jun 30, 2026 was $9.30M. For fiscal 2025 it was -$80.80M. The highest annual figure on record is -$24.05M in fiscal 2017.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$80.80M | – |
| FY2024 | Dec 31, 2024 | -$198.90M | – |
| FY2023 | Dec 31, 2023 | -$367.30M | – |
| FY2022 | Dec 31, 2022 | -$282.50M | – |
| FY2021 | Dec 31, 2021 | -$191.00M | – |
| FY2020 | Dec 31, 2020 | -$119.30M | – |
| FY2019 | Dec 31, 2019 | -$70.30M | – |
| FY2018 | Dec 31, 2018 | -$41.48M | – |
| FY2017 | Dec 31, 2017 | -$24.05M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $169.40M | – |
| Q1 FY2026 | Mar 31, 2026 | -$57.60M | -169.5% |
| Q4 FY2025 | Dec 31, 2025 | -$67.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$35.10M | – |
| Q2 FY2025 | Jun 30, 2025 | -$61.20M | – |
| Q1 FY2025 | Mar 31, 2025 | $82.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$45.10M | – |
| Q3 FY2024 | Sep 30, 2024 | -$49.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -$35.20M | – |
| Q1 FY2024 | Mar 31, 2024 | -$69.40M | – |
| Q4 FY2023 | Dec 31, 2023 | -$154.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$64.00M | – |
| Q2 FY2023 | Jun 30, 2023 | -$66.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$81.90M | – |
| Q4 FY2022 | Dec 31, 2022 | -$82.90M | – |
| Q3 FY2022 | Sep 30, 2022 | -$66.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$70.00M | – |
| Q1 FY2022 | Mar 31, 2022 | -$63.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$53.00M | – |
| Q3 FY2021 | Sep 30, 2021 | -$46.80M | – |
| Q2 FY2021 | Jun 30, 2021 | -$50.30M | – |
| Q1 FY2021 | Mar 31, 2021 | -$41.00M | – |
| Q4 FY2020 | Dec 31, 2020 | -$41.51M | – |
| Q3 FY2020 | Sep 30, 2020 | -$30.82M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.23M | – |
| Q1 FY2020 | Mar 31, 2020 | -$21.74M | – |
| Q4 FY2019 | Dec 31, 2019 | -$21.05M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.68M | – |
| Q2 FY2019 | Jun 30, 2019 | -$17.16M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.40M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.09M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.39M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.85M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.15M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.73M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.40M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.68M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.25M | – |
See a number that looks wrong?